FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...

Health Secretary Robert F. Kennedy Jr. has directed the Food and Drug Administration to review the nutrients and other ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) has suspended dosing in its Danon disease gene therapy trial after a patient ...

Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.

US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease: Cranbury, New Jersey Wednesday, May 28, 2025, 14:00 Hrs [IST] Rocket P ...

Rocket CRM, a SaaS platform designed to help businesses manage and optimize their customer interactions, has introduced a ...

The Space Launch System rocket's RS-25 engine was fired up for the “final round of certification testing ahead of production ...

Research news last week included Rocket Pharmaceuticals suffering a setback with its Phase II trial of RP-A501, which ...

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety ...

China is developing reusable rockets to launch in 2025 and 2026. See the 'net' technology they will use to catch the booster ...